Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.81 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.81 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.81 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.81 |
| ▸ | LMNA | P02545 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.81 |
| ▸ | HTR1A | P08908 | 5/20 | 0.81 |
| ▸ | TP53 | P04637 | 5/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.81 |
| ▸ | DRD1 | P21728 | 4/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.81 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorpromazine SCHEMBL8701718 | 1.00 | CYP1A2 (0.81) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Chlorpromazine SCHEMBL3147615 | 0.92 | CYP1A2 (0.86) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Chlorpromazine SCHEMBL29367385 | 0.90 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Chlorpromazine SCHEMBL29358018 | 0.90 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Promazine SCHEMBL5059998 | 0.90 | CYP2D6 (0.76) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Chlorpromazine SCHEMBL8321 | 0.90 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Promazine SCHEMBL5060002 | 0.90 | CYP2D6 (0.76) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Chlorpromazine SCHEMBL21635684 | 0.89 | CYP1A2 (0.84) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Chlorpromazine SCHEMBL23326209 | 0.89 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 | |
| Chlorpromazine SCHEMBL5483904 | 0.89 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0608322-B1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON VICKS INC (US) | 1998-07-22 | — | — | EP | claimed |
| US-5773023-A | BLEND OF AQUEOUS CARRIER, ACTIVE MATERIAL AND POLYACRYLAMIDE | RICHARDSON-VICKS INC. (US) | 1998-06-30 | — | — | US | claimed |
| EP-0608320-B1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON VICKS INC (US) | 1998-01-28 | — | — | EP | claimed |
| EP-0652774-B1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | PROCTER & GAMBLE (US) | 1997-05-07 | — | — | EP | claimed |
| US-5614178-A | TRANSDERMAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-03-25 | — | — | US | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| CN-1072602-A | Improve the enhanced dermal osmosis system of the local conveying of medicine | RICHARDSON VICKS INC (US) | 1993-06-02 | — | — | CN | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| CN-114891070-A | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-112741817-A | Novel effervescent preparation drug delivery system | 江苏集萃新型药物制剂技术研究所有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-109923101-B | Cyclic compound | 武田药品工业株式会社 | 2021-03-09 | — | — | CN | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |